Harmony Biosciences (HRMY) reported Q4 adjusted earnings Tuesday of $1.08 per diluted share, compared with $0.73 a year earlier.
Analysts surveyed by FactSet expected $0.88.
Net product revenue for the quarter ended Dec. 31 was $201.3 million, compared with $168.4 million a year earlier. Analysts surveyed by FactSet expected $201 million.
The company said it expects net product revenue of $820 million to $860 million for 2025. Analysts surveyed by FactSet expect $844.4 million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.